Clinical Trial Update: Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study recruiting to test adding venetoclax and/or blinatumomab to standard chemotherapy in infants with newly diagnosed KMT2A-rearranged or KMT2A-non-re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Leukemia of Ambiguous Lineage

Drugs mentioned

• Blinatumomab (blinatumomab)
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING